Possibilities of respiratory viral infections therapy under the conditions of etiological diversity


DOI: https://dx.doi.org/10.18565/therapy.2023.2.38-46

Pozdnyakova M.G., Vakin V.S., Esaulenko E.V.

1) Saint Petersburg State Pediatric Medical University of the Ministry of Healthcare of Russia; 2) A.A. Smorodintsev Research Institute of Influenza of the Ministry of Healthcare of Russia, Saint Petersburg
Abstract. The problem of the combined development and interconnection of ARVI and influenza-related parasitic systems occupies more and more space in the theory and practice of epidemic research. Occurrence of the upper respiratory tract pathologies caused by seasonal mixed circulation of influenza viruses and other acute respiratory viral infections in humans is of great concern now. Use of interferon inducers as antiviral and immunomodulating agents is an important approach to the treatment of acute respiratory viral infections.
Aim and methods of the research. Estimation of the incidence of acute respiratory viral infections and grippe in Saint Petersburg and the Kaliningrad region, as well as an estimation of vaccination as a factor influencing a self-regulating epidemic process was performed within the framework of this study. Use of an interferon inducer with various methods of administration in patients with diagnoses «ARVI» and «influenza» of moderate severity with an uncomplicated clinical course was studied.
Results and conclusion. Active co-circulation of numerous ARVI pathogens (influenza viruses, adenoviruses, parainfluenza viruses, metopneumovirus, bocavirus, coronavirus, etc.) was fixed. Such a large number and heterogeneity of ARVI pathogens requires the use of medicines that actively affect the entire group of viruses. The type of reported morbidity associated with respiratory viruses is very diverse and has undergone a pronounced transformation in recent years. At the same time, active vaccination against influenza leads to changes in the course of the annual epidemic seasons for influenza and ARVI. A promising interferon inducer has been identified; it increases the body’s resistance to infectious effects and can be successfully used to treat viral respiratory infections.
Keywords: incidence of influenza and ARVI, treatment of influenza and ARVI, ARVI, influenza
Read entire article

Literature

1. Радаева О.А., Таганов А.В., Рогожина Е.А. Перспективы использования индукторов интерферона на основе двуспиральной РНК для лечения вирусных и бактериальных инфекций. РМЖ. Медицинское обозрение. 2022; 6(11): 643–649. [Radaeva O.A., Taganov A.V., Rogozhina E.A. Prospects of using interferon inducers of the double stranded RNA type for the treatment of viral and bacterial infections. Russkiy meditsinskiy zhurnal. Meditsinskoye obozreniye = Russian Medical Journal. Medical Review. 2022; 6(11): 643–649 (In Russ.)]. https://dx.doi.org/10.32364/2587-6821-2022-6-11-643-649. EDN: MXARSK.


2. Государственный реестр лекарственных средств Минздрава России. Инструкция по медицинскому применению препарат РАДАМИН®ВИРО (дата переоформления: 27.12.2021). Доступ: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=2e3ad776-6616-4e43-99c1-3133cd95b280 (дата обращения – 01.03.2023). [State Register of Medicines of the Ministry of Healthcare of Russia. Instructions for medical use of the drug RADAMIN®VIRO (date of renewal: 12/27/2021). URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=2e3ad776-6616-4e43-99c1-3133cd95b280 (date of access – 01.03.2023) (In Russ.)].


3. Государственные доклады Роспотребнадзора «О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации», 2010–2020 гг. Доступ: https://www.rospotrebnadzor.ru/ (дата обращения – 01.03.2023). [State reports of Rospotrebnadzor «On the state of sanitary and epidemiological welfare of the population in the Russian Federation», 2010–2020. URL: https://www.rospotrebnadzor.ru/ (date of access – 01.03.2023) (In Russ.)].


4. Жигарловский Б.А., Салтыкова Т.С., Брико Н.И. с соавт. Особенности эпидемического процесса острых респираторных инфекций, вызванных разными этиологическими агентами. Эпидемиология и инфекционные болезни. Актуальные вопросы. 2020; 10(4): 45–51. [Zhigarlovsky B.A., Saltykova T.S., Briko N.I. et al. The specific features of the epidemic process of acute respiratory infections caused by different etiological agents. Epidemiologiya i infektsionnyye bolezni. Aktual’nyye voprosy = Epidemiology and Infectious Diseases. Topical Issues. 2020; 10(4): 45–51 (In Russ.)]. https://dx.doi.org/10.18565/epidem.2020.10.4.45-51. EDN: UGJZBL.


5. Вакин В.С., Амосова И.В., Войцеховская Е.М. с соавт. Анализ иммуногенности вакцинного штамма вируса гриппа А(H1N1)pdm09 в пандемию и постпандемический период (2009–2014 гг.) с использованием графического метода. Инфекция и иммунитет. 2022; 12(1): 158–164. [Vakin V.S., Amosova I.V., Vojcekhovskaya E.M. et al. Immunograph-based analysis of the influenza A(H1N1)PDM09 vaccine strain immunogenicity in the pandemic and post-pandemic period (2009–2014). Infektsiya i immunitet = Russian Journal of Infection and Immunity. 2022; 12(1): 158–164 (In Russ.)]. https://dx.doi.org/10.15789/2220-7619-IAO-1693. EDN: ECAGWI.


6. Брико Н.И., Никифоров В.В., Суранова Т.Г. с соавт. Иммунопрофилактика и лечение гриппа: успехи и проблемы. Лечащий врач. 2019; (12): 53–58. [Briko N.I., Nikiforov V.V., Suranova T.G. et al. Influenza immunoprophylaxis and treatment: Progress and challenges. Lechashchiy vrach = Attending Physician. 2019; (12): 53–58 (In Russ.)]. EDN: BIWQYB.


7. Ершов Ф.И., Киселев О.И. Интерфероны и их индукторы (от молекул до лекарств). М.: ГЭОТАР-Медиа. 2005; 356 с. [Ershov F.I., Kiselev O.I. Interferons and their inducers (from molecules to drugs). Moscow: GEOTAR-Media. 2005; 356 p. (In Russ.)]. ISBN: 5-9704-0060-2.


8. Шульдяков А.А., Ляпина Е.П., Соболева Л.А. с соавт. Использование индукторов интерферона в клинике инфекционных болезней. Антибиотики и химиотерапия. 2018; 63(3–4): 28–36. [Shuldyakov A.A., Lyapina E.P., Soboleva L.A. et al. The use of interferon inducers in an infectious disease clinic. Antibiotiki i khimioterapiya = Antibiotics and Chemotherapy. 2018; 63(3–4): 28–36 (In Russ.)]. EDN: XTGEPZ.


About the Autors

Marina G. Pozdnyakova, PhD in Medical Sciences, associate professor of the Department of adult infectious diseases and epidemiology, Saint Petersburg State Pediatric Medical University of the Ministry of Healthcare of Russia. Address: 194100, Saint Petersburg, 2 Litovskaya Str. E-mail: pozdnjakova72@mail.ru. ORCID: https://orcid.org/0000-0003-4915-3326
Vladimir S. Vakin, PhD in Medical Sciences, researcher at A.A. Smorodintsev Research Institute of Influenza of the Ministry of Healthcare of Russia. Address: 197022, Russia, Saint Petersburg, 15/17 Professora Popova Str.
Elena V. Esaulenko, MD, professor, head of the Department of adult infectious diseases and epidemiology, Saint Petersburg State Pediatric Medical University of the Ministry of Healthcare of Russia. Address: 194100, Saint Petersburg, 2 Litovskaya Str. E-mail: eve-gpmu@mail.ru. ORCID: https://orcid.org/0000-0003-3669-1993


Similar Articles

Back to Content

Бионика Медиа